Palvella Rare Disease Day 2017 With A Commitment To Provide New Insights Into Rare Diseases Equipment & Supplies
2 equipment items found
by:Palvella Therapeutics. based inWayne, PENNSYLVANIA (USA)
QTORIN™ rapamycin 3.9% is a novel targeted topical therapy being studied for Microcystic Lymphatic Malformations (Micro LM). Palvella is enrolling a phase 2 clinical study for people with Micro ...
by:Palvella Therapeutics. based inWayne, PENNSYLVANIA (USA)
QTORIN™ rapamycin 3.9%is a novel targeted topical therapy being studied for Gorlin syndrome. Palvella is enrolling a phase 2b clinical study (CODY) for people with Gorlin ...